Table 1.
General characteristics of eligible studies
| All trials (n=64) | Trials eligible for network meta-analysis (n=54) | ||
|---|---|---|---|
| Eligible patients | 7302 | 7014 | |
| Sample size | 66 (31–159) | 81 (40–168) | |
| Eligible arms | 148 | 127 | |
| Number of arms | |||
| Two | 51 (80%) | 42 (78%) | |
| Three | 6 (9%) | 5 (9%) | |
| Four | 7 (11%) | 7 (13%) | |
| Year of publication | |||
| 1980–90 | 10 (16%) | 4 (7%) | |
| 1991–2000 | 27 (42%) | 23 (43%) | |
| 2001–12 | 27 (42%) | 27 (50%) | |
| Type of intervention | |||
| Medication only | 38 (59%) | 33 (61%) | |
| Psychotherapy only | 18 (28%) | 15 (28%) | |
| Both | 8 (13%) | 6 (11%) | |
| Duration (weeks) | 12 (10–12) | 12 (10–12) | |
| Continent | |||
| North America | 30 (47%) | 26 (48%) | |
| Europe | 19 (30%) | 14 (26%) | |
| Asia | 6 (9%) | 6 (11%) | |
| Australia | 3 (5%) | 2 (4%) | |
| South America | 3 (5%) | 3 (6%) | |
| Multiple | 3 (5%) | 3 (6%) | |
| Characteristics of included patients | |||
| Age (years) | 36 (33–37) | 36 (33–37) | |
| Disease severity (YBOCS score) | NA | 25 (24–26) | |
| Comorbid depression | 27 (42%) | 19 (35%) | |
| Pharmaceutical industry sponsorship* | |||
| Yes | 28/46 (61%) | 25/39 (64%) | |
| No | 15/46 (33%) | 12/39 (31%) | |
| Unclear | 3/46 (7%) | 2/39 (5%) | |
| Allowed patients on antidepressant medication† | |||
| Yes | 13/18 (72%) | 12/15 (80%) | |
| No | 4/18 (22%) | 2/15 (13%) | |
| Unclear | 1/18 (6%) | 1/15 (7%) | |
Data are n, median (IQR), n (%), or n/N (%). YBOCS=Yale-Brown Obsessive Compulsive Scale. NA=Not applicable.
*
For pharmacological trials.
†
For psychotherapeutic trials.